The FDA has officially approved ziftomenib, a first-in-class menin inhibitor, for adults with relapsed/refractory AML harboring an NPM1 mutation who lack satisfactory alternative options.
Trial Data (KOMET-001)
In the KOMET-001 trial, ziftomenib 600 mg daily produced a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of approximately 21%. Responses were meaningful in depth, with a median duration of CR/CRh of around five months. Patients typically responded early, with the median time to first CR/CRh occurring at about 2.7 months, and the overall response rate was roughly 33%. Notably, several responders achieved MRD negativity and became transfusion-independent. The approved dose is 600 mg orally once daily, and the label includes a boxed warning for differentiation syndrome.
Clinical Implications:
This approval provides a targeted oral therapy for NPM1-mutated R/R AML—a population with limited durable options after HMA/venetoclax or intensive regimens. It reinforces the need for routine NPM1 testing at diagnosis and relapse and preparation for DS monitoring and early steroid intervention.
A meaningful milestone for precision oncology in AML and an exciting step in the evolution of menin inhibition.